SCHEMBL7043932

SCHEMBL7043932

COc1nn(-c2ccc(NC(=O)Cc3ccc(Cl)cc3)cc2)c(=O)o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 1/20 0.56
LIPC P11150 1/20 0.56
LIPE Q05469 1/20 0.56
MAPT P10636 3/20 0.51
RXFP1 Q9HBX9 1/20 0.50
ABHD16A O95870 1/20 0.50
TP53 P04637 3/20 0.48
FAAH O00519 3/20 0.48
MGLL Q99685 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KDR P35968 1/20 0.46
KLK7 P49862 1/20 0.46
KDM4E B2RXH2 1/20 0.45
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7046273 0.85 FAAH (0.60) LPLLIPCLIPEMAPTABHD16A
SCHEMBL7044315 0.85 MGLL (0.62) LPLLIPCLIPEMAPTRXFP1
SCHEMBL6600164 0.83 FAAH (0.56) LPLLIPCLIPEMAPTFAAH
SCHEMBL2233406 0.81 ABHD16A (0.72) LPLLIPCLIPEABHD16AFAAH
SCHEMBL7653362 0.78 FAAH (0.49) MAPTABHD16ATP53FAAHMGLL
SCHEMBL7046159 0.78 LPL (0.58) LPLLIPCLIPEMAPTABHD16A
SCHEMBL6601946 0.77 LPL (0.57) LPLLIPCLIPEABHD16AFAAH
SCHEMBL6604642 0.77 LPL (0.62) LPLLIPCLIPEABHD16AFAAH
SCHEMBL6603090 0.76 LPL (0.60) LPLLIPCLIPEABHD16AFAAH
SCHEMBL7044439 0.75 MGLL (0.78) LPLLIPCLIPEABHD16AFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 LPL 1845/4885LIPC 554/4885LIPE 1909/4885
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE LPL 4/4885LIPC 7/4885LIPE 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.